Arrivent Biopharma Inc (AVBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 282,855 | 298,669 | 317,393 | 150,389 | 0 |
| TOTAL | $292,398 | $308,511 | $327,480 | $159,968 | $0 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 313 | 344 | 358 | 3,130 | 0 |
| TOTAL | $313 | $344 | $358 | $3,130 | $N/A |
| Total Assets | $292,711 | $308,855 | $327,838 | $163,098 | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,646 | 3,812 | 4,098 | 4,532 | 0 |
| Accrued Expenses | 10,359 | 8,134 | 5,732 | 6,952 | 0 |
| TOTAL | $15,162 | $12,098 | $9,977 | $11,624 | $0 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 56 | 98 | 138 | 177 | 0 |
| TOTAL | $56 | $98 | $138 | $177 | $N/A |
| Total Liabilities | $15,218 | $12,196 | $10,115 | $11,801 | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 33,697 | 33,586 | 33,494 | N/A | N/A |
| Common Shares | 3 | 3 | 3 | N/A | 0 |
| Retained earnings | -217,700 | -197,136 | -175,262 | -157,845 | 0 |
| Other shareholders' equity | 0 | 0 | 0 | 304,490 | 0 |
| TOTAL | $277,493 | $296,659 | $317,723 | $151,297 | $0 |
| Total Liabilities And Equity | $292,711 | $308,855 | $327,838 | $163,098 | $0 |